One of the anticipated applications of stem cell research in clinics is Parkinson’s disease (PD). Open-label clinical trials of cell therapies for PD have been conducted using aborted fetal tissues since the 1980s. Some patients showed favorable outcomes that lasted more than 10 years. These therapies, however, suffer from several problems, such as a short supply of donor materials, unstable quality of the donor cells, and ethical restrictions. As an alternative donor source to fetal tissues, researchers have developed methods to differentiate dopaminergic neural progenitors from stem cells, especially pluripotent stem cells (PSCs). PSC-derived donor cells have been prepared at clinical grade, and their efficacies and safeties were confirmed in non-clinical studies, leading to clinical trials. While promising, there are several practical points to improve in stem cell-based therapies for PD: the quality of donor cells, immune control to avoid graft rejection, surgical procedures for grafting, and the indications for the cell therapy.